;PMID: 7870052
;source_file_879.mrg
;Release 0.9 of PennBioIE
;Funded by NSF ITR EIA-0205448

;0)section:[e:0..36] = [t:0..36]
;1)sentence:[e:42..111] = [t:42..111]
;2)section:[e:115..226] = [t:115..226]
;3)section:[e:230..270] = [t:230..270]
;4)sentence:[e:274..489] = [t:274..489]
;5)sentence:[e:490..699] = [t:490..699]
;6)sentence:[e:700..846] = [t:700..846]
;7)sentence:[e:847..1034] = [t:847..1034]
;8)sentence:[e:1035..1231] = [t:1035..1231]
;9)sentence:[e:1232..1453] = [t:1232..1453]
;10)sentence:[e:1455..1574] = [t:1455..1574]
;11)sentence:[e:1575..1828] = [t:1575..1828]
;12)sentence:[e:1829..2067] = [t:1829..2067]
;13)section:[e:2071..2115] = [t:2071..2115]

;section 0 Span:0..36
;Mol Pharmacol. 1995 Feb;47(2):410-8.
(SEC
  (FRAG (NNP:[0..3] Mol) (NNP:[4..13] Pharmacol) (.:[13..14] .)
        (CD:[15..19] 1995) (.:[20..27] Feb;47-LRB-) (CD:[27..28] 2)
        (-RRB-:[28..29] -RRB-) (CD:[29..33] :410) (::[33..34] -)
        (CD:[34..36] 8.)))

;sentence 1 Span:42..111
;Oxidative metabolism of lansoprazole by human liver cytochromes P450.
;[66..78]:substance:"lansoprazole"
;[94..110]:cyp450:"cytochromes P450"
(SENT
  (NP-HLN
    (NP (JJ:[42..51] Oxidative) (NN:[52..62] metabolism))
    (PP (IN:[63..65] of)
      (NP (NN:[66..78] lansoprazole)))
    (PP (IN:[79..81] by)
      (NP (JJ:[82..87] human) (NN:[88..93] liver)
         (NNS:[94..105] cytochromes) (NN:[106..110] P450)))
    (.:[110..111] .)))

;section 2 Span:115..226
;Pichard L, Curi-Pedrosa R, Bonfils C, Jacqz-Aigrain E, Domergue J, Joyeux H, 
;Cosme J, Guengerich FP, Maurel P.
(SEC
  (FRAG (NNP:[115..122] Pichard) (NNP:[123..125] L,) (NNP:[126..130] Curi)
        (::[130..131] -) (NNP:[131..138] Pedrosa) (NNP:[139..141] R,)
        (NNP:[142..149] Bonfils) (NNP:[150..151] C) (,:[151..152] ,)
        (NNP:[153..158] Jacqz) (::[158..159] -) (NNP:[159..166] Aigrain)
        (NNP:[167..168] E) (,:[168..169] ,) (NNP:[170..178] Domergue)
        (NNP:[179..181] J,) (NNP:[182..188] Joyeux) (NNP:[189..190] H)
        (,:[190..191] ,) (NNP:[193..198] Cosme) (NNP:[199..201] J,)
        (NNP:[202..212] Guengerich) (NNP:[213..215] FP) (,:[215..216] ,)
        (NNP:[217..223] Maurel) (NNP:[224..226] P.)))

;section 3 Span:230..270
;INSERM U-128, CNRS, Montpellier, France.
(SEC
  (FRAG (NNP:[230..236] INSERM) (NNP:[237..239] U-) (CD:[239..242] 128)
        (,:[242..243] ,) (NNP:[244..248] CNRS) (,:[248..249] ,)
        (NNP:[250..261] Montpellier) (,:[261..262] ,) (NNP:[263..269] France)
        (.:[269..270] .)))

;sentence 4 Span:274..489
;The aim of this work was to identify the form(s) of human cytochrome P450
;(P450)  involved in the hepatic biotransformation of lansoprazole to its two
;main  metabolites, i.e., the sulfone and the hydroxy derivative.
;[332..347]:cyp450:"cytochrome P450"
;[349..353]:cyp450:"P450"
;[401..413]:substance:"lansoprazole"
;[431..442]:substance:"metabolites"
;[454..461]...[478..488]:substance:"sulfone"..."derivative"
;[470..488]:substance:"hydroxy derivative"
(SENT
  (S
    (NP-SBJ
      (NP (DT:[274..277] The) (NN:[278..281] aim))
      (PP (IN:[282..284] of)
        (NP (DT:[285..289] this) (NN:[290..294] work))))
    (VP (VBD:[295..298] was)
      (S-PRP-PRD
        (NP-SBJ (-NONE-:[298..298] *))
        (VP (TO:[299..301] to)
          (VP (VB:[302..310] identify)
            (NP
              (NP
                (NP (DT:[311..314] the) (NN:[315..322] form-LRB-s-RRB-))
                (PP (IN:[323..325] of)
                  (NP (JJ:[326..331] human)
                    (NML
                      (NML (NN:[332..342] cytochrome) (NN:[343..347] P450))
                      (NML (-LRB-:[348..349] -LRB-) (NN:[349..353] P450)
                           (-RRB-:[353..354] -RRB-))))))
              (VP (VBN:[356..364] involved)
                (NP (-NONE-:[364..364] *))
                (PP-CLR (IN:[365..367] in)
                  (NP
                    (NP (DT:[368..371] the) (JJ:[372..379] hepatic)
                        (NN:[380..397] biotransformation))
                    (PP (IN:[398..400] of)
                      (NP (NN:[401..413] lansoprazole)))
                    (PP (TO:[414..416] to)
                      (NP
                        (NP (PRP$:[417..420] its) (CD:[421..424] two)
                            (JJ:[425..429] main) (NNS:[431..442] metabolites))
                        (,:[442..443] ,)
                        (NP
                          (ADVP (FW:[444..448] i.e.))
                          (,:[448..449] ,)
                          (NP (DT:[450..453] the) (NN:[454..461] sulfone)
                            (NML-1 (-NONE-:[461..461] *P*)))
                          (CC:[462..465] and)
                          (NP (DT:[466..469] the)
                             (NN:[470..477] hydroxy)
                            (NML-1 (NN:[478..488] derivative))))))))))))))
    (.:[488..489] .)))

;sentence 5 Span:490..699
;In liver microsomes,  the production of the sulfone of lansoprazole
;correlated with the level of P450  3A4, cyclosporin oxidase, and the
;production of the hydroxy derivative, as well  as of omeprazole sulfone.
;[534..541]:substance:"sulfone"
;[545..557]:substance:"lansoprazole"
;[587..596]:cyp450:"P450  3A4"
;[598..617]:substance:"cyclosporin oxidase"
;[645..663]:substance:"hydroxy derivative"
;[680..698]:substance:"omeprazole sulfone"
(SENT
  (S
    (PP-LOC (IN:[490..492] In)
      (NP (NN:[493..498] liver) (NNS:[499..509] microsomes)))
    (,:[509..510] ,)
    (NP-SBJ
      (NP (DT:[512..515] the) (NN:[516..526] production))
      (PP (IN:[527..529] of)
        (NP
          (NP (DT:[530..533] the) (NN:[534..541] sulfone))
          (PP (IN:[542..544] of)
            (NP (NN:[545..557] lansoprazole))))))
    (VP (VBD:[558..568] correlated)
      (PP-CLR (IN:[569..573] with)
        (NP
          (NP (DT:[574..577] the) (NN:[578..583] level))
          (PP (IN:[584..586] of)
            (NP
              (NP (NN:[587..591] P450) (NN:[593..596] 3A4))
              (,:[596..597] ,)
              (NP (NN:[598..609] cyclosporin) (NN:[610..617] oxidase))
              (,:[617..618] ,) (CC:[619..622] and)
              (NP
                (NP (DT:[623..626] the) (NN:[627..637] production))
                (PP
                  (PP (IN:[638..640] of)
                    (NP (DT:[641..644] the)
                       (NN:[645..652] hydroxy) (NN:[653..663] derivative)))
                  (,:[663..664] ,)
                  (CONJP (RB:[665..667] as) (RB:[668..672] well)
                         (IN:[674..676] as))
                  (PP (IN:[677..679] of)
                    (NP (NN:[680..690] omeprazole) (NN:[691..698] sulfone))))))))))
    (.:[698..699] .)))

;sentence 6 Span:700..846
;The production of hydroxylansoprazole moderately  correlated with the level
;of P450 3A4, cyclosporin oxidase, and (S)-mephenytoin  4'-hydroxylase.
;[718..737]:substance:"hydroxylansoprazole"
;[779..787]:cyp450:"P450 3A4"
;[789..808]:substance:"cyclosporin oxidase"
;[814..845]:cyp450:"(S)-mephenytoin  4'-hydroxylase"
(SENT
  (S
    (NP-SBJ
      (NP (DT:[700..703] The) (NN:[704..714] production))
      (PP (IN:[715..717] of)
        (NP (NN:[718..737] hydroxylansoprazole))))
    (ADVP (RB:[738..748] moderately))
    (VP (VBD:[750..760] correlated)
      (PP-CLR (IN:[761..765] with)
        (NP
          (NP (DT:[766..769] the) (NN:[770..775] level))
          (PP (IN:[776..778] of)
            (NP
              (NP (NN:[779..783] P450) (NN:[784..787] 3A4))
              (,:[787..788] ,)
              (NP (NN:[789..800] cyclosporin) (NN:[801..808] oxidase))
              (,:[808..809] ,) (CC:[810..813] and)
              (NP (NN:[814..829] -LRB-S-RRB--mephenytoin)
                  (NN:[831..845] 4'-hydroxylase)))))))
    (.:[845..846] .)))

;sentence 7 Span:847..1034
;The production of the sulfone and of the hydroxy derivative of  lansoprazole
;was significantly inhibited by anti-P450 3A4 antibodies, by  cyclosporin and
;ketoconazole, and by tolbutamide.
;[869..876]...[896..906]:substance:"sulfone"..."derivative"
;[888..906]:substance:"hydroxy derivative"
;[911..923]:substance:"lansoprazole"
;[955..979]:substance:"anti-P450 3A4 antibodies"
;[985..996]:substance:"cyclosporin"
;[1001..1013]:substance:"ketoconazole"
;[1022..1033]:substance:"tolbutamide"
(SENT
  (S
    (NP-SBJ-3
      (NP (DT:[847..850] The) (NN:[851..861] production))
      (PP
        (PP (IN:[862..864] of)
          (NP
            (NP (DT:[865..868] the) (NN:[869..876] sulfone)
              (NML-1 (-NONE-:[876..876] *P*)))
            (PP-2 (-NONE-:[876..876] *P*))))
        (CC:[877..880] and)
        (PP (IN:[881..883] of)
          (NP
            (NP (DT:[884..887] the)
               (NN:[888..895] hydroxy)
              (NML-1 (NN:[896..906] derivative)))
            (PP-2 (IN:[907..909] of)
              (NP (NN:[911..923] lansoprazole)))))))
    (VP (VBD:[924..927] was)
      (ADVP (RB:[928..941] significantly))
      (VP (VBN:[942..951] inhibited)
        (NP-3 (-NONE-:[951..951] *))
        (PP
          (PP (IN:[952..954] by)
            (NP-LGS
              (NML (AFX:[955..959] anti) (HYPH:[959..960] -)
                   (NN:[960..964] P450) (NN:[965..968] 3A4))
              (NNS:[969..979] antibodies)))
          (,:[979..980] ,)
          (PP (IN:[981..983] by)
            (NP-LGS (NN:[985..996] cyclosporin) (CC:[997..1000] and)
                    (NN:[1001..1013] ketoconazole)))
          (,:[1013..1014] ,) (CC:[1015..1018] and)
          (PP (IN:[1019..1021] by)
            (NP-LGS (NN:[1022..1033] tolbutamide))))))
    (.:[1033..1034] .)))

;sentence 8 Span:1035..1231
;Anti-P450 2C8 and 2C3  antibodies moderately inhibited the biotransformation
;of lansoprazole, whereas  they completely inhibited (S)-mephenytoin
;4'-hydroxylase activity under the same  conditions.
;[1035..1048]...[1058..1068]:substance:"Anti-P450 2C8"..."antibodies"
;[1035..1044]...[1053..1068]:substance:"Anti-P450"..."2C3  antibodies"
;[1115..1127]:substance:"lansoprazole"
;[1164..1194]:cyp450:"(S)-mephenytoin 4'-hydroxylase"
(SENT
  (S
    (NP-SBJ
      (NP
        (NML
          (ADJP-2 (AFX:[1035..1039] Anti))
          (HYPH:[1039..1040] -)
          (NML-1 (NN:[1040..1044] P450))
          (NN:[1045..1048] 2C8))
        (NML-3 (-NONE-:[1048..1048] *P*)))
      (CC:[1049..1052] and)
      (NP
        (NML
          (ADJP-2 (-NONE-:[1052..1052] *P*))
          (NML-1 (-NONE-:[1052..1052] *P*))
          (NN:[1053..1056] 2C3))
        (NML-3 (NNS:[1058..1068] antibodies))))
    (ADVP (RB:[1069..1079] moderately))
    (VP (VBD:[1080..1089] inhibited)
      (NP
        (NP (DT:[1090..1093] the) (NN:[1094..1111] biotransformation))
        (PP (IN:[1112..1114] of)
          (NP (NN:[1115..1127] lansoprazole))))
      (,:[1127..1128] ,)
      (SBAR-ADV (IN:[1129..1136] whereas)
        (S
          (NP-SBJ (PRP:[1138..1142] they))
          (ADVP (RB:[1143..1153] completely))
          (VP (VBD:[1154..1163] inhibited)
            (NP
              (NML (NN:[1164..1179] -LRB-S-RRB--mephenytoin)
                   (NN:[1180..1194] 4'-hydroxylase))
              (NN:[1195..1203] activity))
            (PP (IN:[1204..1209] under)
              (NP (DT:[1210..1213] the) (JJ:[1214..1218] same)
                  (NNS:[1220..1230] conditions)))))))
    (.:[1230..1231] .)))

;sentence 9 Span:1232..1453
;In primary cultures of human hepatocytes, the biotransformation of 
;lansoprazole and the oxidation of cyclosporin were strongly increased by 
;rifampicin and phenobarbital, whereas (S)-mephenytoin 4'-hydroxylation was
;not.
;[1300..1312]:substance:"lansoprazole"
;[1334..1345]:substance:"cyclosporin"
;[1374..1384]:substance:"rifampicin"
;[1389..1402]:substance:"phenobarbital"
;[1412..1427]:substance:"(S)-mephenytoin"
(SENT
  (S
    (PP-LOC (IN:[1232..1234] In)
      (NP
        (NP (JJ:[1235..1242] primary) (NNS:[1243..1251] cultures))
        (PP (IN:[1252..1254] of)
          (NP (JJ:[1255..1260] human) (NNS:[1261..1272] hepatocytes)))))
    (,:[1272..1273] ,)
    (NP-SBJ-1
      (NP
        (NP (DT:[1274..1277] the) (NN:[1278..1295] biotransformation))
        (PP (IN:[1296..1298] of)
          (NP (NN:[1300..1312] lansoprazole))))
      (CC:[1313..1316] and)
      (NP
        (NP (DT:[1317..1320] the) (NN:[1321..1330] oxidation))
        (PP (IN:[1331..1333] of)
          (NP (NN:[1334..1345] cyclosporin)))))
    (VP (VBD:[1346..1350] were)
      (ADVP (RB:[1351..1359] strongly))
      (VP (VBN:[1360..1369] increased)
        (NP-1 (-NONE-:[1369..1369] *))
        (PP (IN:[1370..1372] by)
          (NP-LGS (NN:[1374..1384] rifampicin) (CC:[1385..1388] and)
                  (NN:[1389..1402] phenobarbital)))
        (,:[1402..1403] ,)
        (SBAR-ADV (IN:[1404..1411] whereas)
          (S
            (NP-SBJ (NN:[1412..1427] -LRB-S-RRB--mephenytoin)
                    (NN:[1428..1444] 4'-hydroxylation))
            (VP (VBD:[1445..1448] was) (RB:[1449..1452] not)
              (VP (-NONE-:[1452..1452] *?*)))))))
    (.:[1452..1453] .)))

;sentence 10 Span:1455..1574
;beta-Naphthoflavone did not induce the formation of the sulfones but
;stimulated  the production of hydroxylansoprazole.
;[1455..1474]:substance:"beta-Naphthoflavone"
;[1511..1519]:substance:"sulfones"
;[1554..1573]:substance:"hydroxylansoprazole"
(SENT
  (S
    (NP-SBJ (NN:[1455..1474] beta-Naphthoflavone))
    (VP
      (VP (VBD:[1475..1478] did) (RB:[1479..1482] not)
        (VP (VB:[1483..1489] induce)
          (NP
            (NP (DT:[1490..1493] the) (NN:[1494..1503] formation))
            (PP (IN:[1504..1506] of)
              (NP (DT:[1507..1510] the) (NNS:[1511..1519] sulfones))))))
      (CC:[1520..1523] but)
      (VP (VBD:[1524..1534] stimulated)
        (NP
          (NP (DT:[1536..1539] the) (NN:[1540..1550] production))
          (PP (IN:[1551..1553] of)
            (NP (NN:[1554..1573] hydroxylansoprazole))))))
    (.:[1573..1574] .)))

;sentence 11 Span:1575..1828
;Among several forms of cDNA-expressed  human P450s, 3A4 generated significant
;amounts of the sulfones of lansoprazole  and omeprazole and 2C18 was active
;for the production of hydroxylansoprazole but  inactive in the
;4'-hydroxylation of (S)-mephenytoin.
;[1598..1602]:substance:"cDNA"
;[1620..1625]...[1713..1717]:cyp450:"P450s"..."2C18"
;[1620..1625]...[1627..1630]:cyp450:"P450s"..."3A4"
;[1668..1676]:substance:"sulfones"
;[1680..1692]:substance:"lansoprazole"
;[1698..1708]:substance:"omeprazole"
;[1751..1770]:substance:"hydroxylansoprazole"
;[1812..1827]:substance:"(S)-mephenytoin"
(SENT
  (S
    (PP-TPC-3 (IN:[1575..1580] Among)
      (NP
        (NP (JJ:[1581..1588] several) (NNS:[1589..1594] forms))
        (PP (IN:[1595..1597] of)
          (NP
            (ADJP (NN:[1598..1602] cDNA) (HYPH:[1602..1603] -)
                  (VBN:[1603..1612] expressed))
            (JJ:[1614..1619] human) (NNS:[1620..1625] P450s)))))
    (,:[1625..1626] ,)
    (S
      (NP-SBJ
        (NP (NN:[1627..1630] 3A4))
        (PP-3 (-NONE-:[1630..1630] *T*)))
      (VP (VBD:[1631..1640] generated)
        (NP
          (NP (JJ:[1641..1652] significant) (NNS:[1653..1660] amounts))
          (PP (IN:[1661..1663] of)
            (NP
              (NP (DT:[1664..1667] the) (NNS:[1668..1676] sulfones))
              (PP (IN:[1677..1679] of)
                (NP (NN:[1680..1692] lansoprazole) (CC:[1694..1697] and)
                    (NN:[1698..1708] omeprazole))))))))
    (CC:[1709..1712] and)
    (S
      (NP-SBJ
        (NP (NN:[1713..1717] 2C18))
        (PP-3 (-NONE-:[1717..1717] *T*)))
      (VP
        (VP (VBD:[1718..1721] was)
          (ADJP-PRD=1 (JJ:[1722..1728] active))
          (PP=2 (IN:[1729..1732] for)
            (NP
              (NP (DT:[1733..1736] the) (NN:[1737..1747] production))
              (PP (IN:[1748..1750] of)
                (NP (NN:[1751..1770] hydroxylansoprazole))))))
        (CC:[1771..1774] but)
        (VP
          (ADJP-PRD=1 (JJ:[1776..1784] inactive))
          (PP=2 (IN:[1785..1787] in)
            (NP
              (NP (DT:[1788..1791] the) (NN:[1792..1808] 4'-hydroxylation))
              (PP (IN:[1809..1811] of)
                (NP (NN:[1812..1827] -LRB-S-RRB--mephenytoin))))))))
    (.:[1827..1828] .)))

;sentence 12 Span:1829..2067
;We conclude that P450 3A4  is the major enzyme involved in the production of
;the sulfone of lansoprazole  and that this P450, as well as P450 2C18 and/or
;another 2C-related form, could  contribute to the production of
;hydroxylansoprazole.
;[1846..1854]:cyp450:"P450 3A4"
;[1869..1875]:cyp450:"enzyme"
;[1910..1917]:substance:"sulfone"
;[1921..1933]:substance:"lansoprazole"
;[1949..1953]:cyp450:"P450"
;[1966..1975]:cyp450:"P450 2C18"
;[1966..1970]...[1991..2006]:cyp450:"P450"..."2C-related form"
;[2047..2066]:substance:"hydroxylansoprazole"
(SENT
  (S
    (NP-SBJ (PRP:[1829..1831] We))
    (VP (VBP:[1832..1840] conclude)
      (SBAR
        (SBAR (IN:[1841..1845] that)
          (S
            (NP-SBJ (NN:[1846..1850] P450) (NN:[1851..1854] 3A4))
            (VP (VBZ:[1856..1858] is)
              (NP-PRD
                (NP (DT:[1859..1862] the) (JJ:[1863..1868] major)
                    (NN:[1869..1875] enzyme))
                (VP (VBN:[1876..1884] involved)
                  (NP (-NONE-:[1884..1884] *))
                  (PP-CLR (IN:[1885..1887] in)
                    (NP
                      (NP (DT:[1888..1891] the) (NN:[1892..1902] production))
                      (PP (IN:[1903..1905] of)
                        (NP
                          (NP (DT:[1906..1909] the) (NN:[1910..1917] sulfone))
                          (PP (IN:[1918..1920] of)
                            (NP (NN:[1921..1933] lansoprazole))))))))))))
        (CC:[1935..1938] and)
        (SBAR (IN:[1939..1943] that)
          (S
            (NP-SBJ
              (NP (DT:[1944..1948] this) (NN:[1949..1953] P450))
              (,:[1953..1954] ,)
              (CONJP (RB:[1955..1957] as) (RB:[1958..1962] well)
                     (IN:[1963..1965] as))
              (NP
                (NML (NN:[1966..1970] P450) (NN:[1971..1975] 2C18))
                (CC:[1976..1982] and/or)
                (NP (DT:[1983..1990] another)
                  (ADJP (NN:[1991..1993] 2C) (HYPH:[1993..1994] -)
                        (JJ:[1994..2001] related))
                  (NN:[2002..2006] form))))
            (,:[2006..2007] ,)
            (VP (MD:[2008..2013] could)
              (VP (VB:[2015..2025] contribute)
                (PP-CLR (TO:[2026..2028] to)
                  (NP
                    (NP (DT:[2029..2032] the) (NN:[2033..2043] production))
                    (PP (IN:[2044..2046] of)
                      (NP (NN:[2047..2066] hydroxylansoprazole)))))))))))
    (.:[2066..2067] .)))

;section 13 Span:2071..2115
;PMID: 7870052 [PubMed - indexed for MEDLINE]
(SEC
  (FRAG (NNP:[2071..2075] PMID) (::[2075..2076] :) (CD:[2077..2084] 7870052)
        (NN:[2085..2086] -LSB-) (NNP:[2086..2092] PubMed) (::[2093..2094] -)
        (NN:[2095..2102] indexed) (IN:[2103..2106] for)
        (NNP:[2107..2115] MEDLINE-RSB-)))
